Abstract:Abstract Proton magnetic resonance spectroscopy is a non-invasive method of exploring cerebral metabolism. In Huntington’s disease, altered proton magnetic resonance spectroscopy-determined concentrations of several metabolites have been described; however, findings are often discrepant and longitudinal studies are lacking. Proton magnetic resonance spectroscopy metabolites may represent a source of biomarkers, thus their relationship with established markers of disease progression require further exploration to assess prognostic value and elucidate pathways associated with neurodegeneration. In a prospective single-site controlled cohort study with standardized collection of CSF, blood, phenotypic and volumetric imaging data, we used 3 T proton magnetic resonance spectroscopy in conjunction with the linear combination of model spectra method to quantify seven metabolites (total n-acetylaspartate, total creatine, total choline, myo-inositol, GABA, glutamate and glutathione) in the putamen of 59 participants at baseline (15 healthy controls, 15 premanifest and 29 manifest Huntington’s disease gene expansion carriers) and 48 participants at 2-year follow-up (12 healthy controls, 13 premanifest and 23 manifest Huntington’s disease gene expansion carriers). Intergroup differences in concentration and associations with CSF and plasma biomarkers; including neurofilament light chain and mutant Huntingtin, volumetric imaging markers; namely whole brain, caudate, grey matter and white matter volume, measures of disease progression and cognitive decline, were assessed cross-sectionally using generalized linear models and partial correlation. We report no significant groupwise differences in metabolite concentration at baseline but found total creatine and total n-acetylaspartate to be significantly reduced in manifest compared with premanifest participants at follow-up. Additionally, total creatine and myo-inositol displayed significant associations with reduced caudate volume across both time points in gene expansion carriers. Although relationships were observed between proton magnetic resonance spectroscopy metabolites and biofluid measures, these were not consistent across time points. To further assess prognostic value, we examined whether baseline proton magnetic resonance spectroscopy values, or rate of change, predicted subsequent change in established measures of disease progression. Several associations were found but were inconsistent across known indicators of disease progression. Finally, longitudinal mixed-effects models revealed glutamine + glutamate to display a slow linear decrease over time in gene expansion carriers. Altogether, our findings show some evidence of reduced total n-acetylaspartate and total creatine as the disease progresses and cross-sectional associations between select metabolites, namely total creatine and myo-inositol, and markers of disease progression, potentially highlighting the proposed roles of neuroinflammation and metabolic dysfunction in disease pathogenesis. However, the absence of consistent group differences, inconsistency between baseline and follow-up, and lack of clear longitudinal change suggests that proton magnetic resonance spectroscopy metabolites have limited potential as Huntington’s disease biomarkers.

Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Altered Iron and Microstructure in Huntington's Disease Subcortical Nuclei: Insight From 7T MRI

Altered Brain Iron Depositions from Aging to Parkinson's Disease and Alzheimer's Disease: A Quantitative Susceptibility Mapping Study

Altered brain iron depositions from aging to Parkinson's disease and Alzheimer's disease: A quantitative susceptibility mapping study.

Brain Iron Deposition in White Matter Hyperintensities: a 3-T MRI Study

Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.

Different Iron Deposition Patterns in Early- and Middle-Late-onset Parkinson's Disease.

Genetic Impacts on Nigral Iron Deposition in Parkinson's Disease: A Preliminary Quantitative Susceptibility Mapping Study.

Influence Of Regional Iron On The Motor Impairments Of Parkinson'S Disease: A Quantitative Susceptibility Mapping Study

Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington’s Disease

Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study.

Quantitative Study of the Changes in Cerebral Blood Flow and Iron Deposition During Progression of Alzheimer's Disease.

Age-related Deposition of Brain Iron in Normal Adults:An in Vivo Susceptibility Weighted Imaging Study

Asymmetrical Nigral Iron Accumulation In Parkinson'S Disease With Motor Asymmetry: An Explorative, Longitudinal And Test-Retest Study

Alterations in brain iron deposition with progression of late-life depression measured by magnetic resonance imaging (MRI)-based quantitative susceptibility mapping

Linking White Matter and Deep Gray Matter Alterations in Premanifest Huntington Disease.

Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease

Quantifying Iron Deposition Within the Substantia Nigra of Parkinson's Disease by Quantitative Susceptibility Mapping

Region-specific Disturbed Iron Distribution in Early Idiopathic Parkinson's Disease Measured by Quantitative Susceptibility Mapping.

Mapping the Order and Pattern of Brain Structural MRI Changes Using Change‐point Analysis in Premanifest Huntington's Disease

Age-related iron deposition in the basal ganglia of controls and Alzheimer disease patients quantified using susceptibility weighted imaging.